A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.

Also called NCT02967211

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 609 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02967211
  • EudraCT 2015-001832-39
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil, Finland, France, Greece, Ireland, Italy, Romania, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02967211. Randomized; no masking; primary purpose treatment. Start 2015-12-21 (registry gives no type); primary completion 2017-10-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
Acronym
REGAIN CONTROL
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin glargine (U300)
Intervention (Drug)
insulin glargine (U100)
Intervention (Drug)
NPH insulin
Intervention (Drug)
insulin detemir
Intervention (Drug)
insulin degludec
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02967211
Content hash
320f912e0ec21585215e2c1ea2cce1b3dd1d9a1b9216a50d962c90186e840ac8